Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 7/20 | 0.53 |
| ▸ | MAOB | P27338 | 10/20 | 0.51 |
| ▸ | MAOA | P21397 | 5/20 | 0.47 |
| ▸ | CALML3 | P27482 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | SDHA | P31040 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897203 | 0.82 | CALML3 (0.42) | F10MAOBMAOACALML3LMNA | |
| SCHEMBL21999243 | 0.80 | MAOB (0.57) | F10MAOBMAOACALML3LMNA | |
| SCHEMBL2088562 | 0.80 | F10 (0.58) | F10MAOBMAOACALML3LMNA | |
| SCHEMBL3331210 | 0.79 | CALML3 (0.53) | MAOBMAOACALML3 | |
| SCHEMBL3328449 | 0.79 | CALML3 (0.53) | MAOBMAOACALML3 | |
| SCHEMBL28757341 | 0.79 | MAOB (0.61) | F10MAOBMAOACALML3LMNA | |
| SCHEMBL3197103 | 0.79 | F10 (0.65) | F10MAOBMAOACALML3LMNA | |
| SCHEMBL6629866 | 0.79 | F10 (0.65) | F10MAOBMAOACALML3LMNA | |
| SCHEMBL6110851 | 0.78 | MAOA (0.62) | F10MAOBMAOACALML3LMNA | |
| SCHEMBL6111122 | 0.78 | F10 (0.52) | F10MAOBMAOACALML3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147545-A1 | Derivatives of oxazolidinones as antibacterial agents | LABORATORIOS VITA, S.A. (ES) | 2004-07-29 | — | — | US | disclosed |
| EP-1401834-A1 | NEW DERIVATIVES OF OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | LABORATORIOS VITA, S.A. (ES) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003002560-A1 | NEW DERIVATIVES OF OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | LABORATORIOS VITA, S.A. (ES) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147545-A1 | Derivatives of oxazolidinones as antibacterial agents | OXA1L, Q6ZSR9, PGC | F10 1608/4885MAOB 711/4885MAOA 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.